Amgen Inc. buy melinda
Start price
31.08.17
/
50%
€159.06
Target price
12.09.17
€171.38
Performance (%)
7.96%
End price
12.09.17
€171.72
Summary
This prediction ended on 12.09.17 with a price of €171.72. The BUY prediction by melinda finished with a performance of 7.96%. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Amgen Inc. | -4.004% | -4.004% | 34.956% | 40.625% |
iShares Core DAX® | -0.683% | 1.890% | 15.367% | 17.155% |
iShares Nasdaq 100 | 0.335% | 4.631% | 29.818% | 56.187% |
iShares Nikkei 225® | -1.486% | -2.361% | 7.668% | 3.633% |
iShares S&P 500 | -0.523% | 2.324% | 25.460% | 46.452% |
Comments by melinda for this prediction
In the thread Amgen Inc. diskutieren
zu folgen
$
Wenn in Phase III getestet Kopf an Kopf, das Bestreben, reduziert KYPROLIS und Dexamethason das Sterberisiko um 21% und erhöhte die Überlebenszeit von 7,6 Monaten im Vergleich zu Velcade und Dexamethason in Patienten mit rezidivierendem oder refraktärem multiplem Myelom
(Zielkurs erreicht)